Sorbact® is a registered trademark owned byABIGO Medical AB
Sorbact
Select market
Africa
BotswanaEgyptGhanaKenyaLesothoMauritaniaMauritiusMoroccoMozambiqueNamibiaNigeriaSeychellesSouth AfricaSudanSwazilandTanzaniaUgandaZambiaAsia-Pacific
AustraliaBahrainChinaHong KongIndiaIndonesiaIraqJapanJordanKuwaitMacaoNew ZealandOmanPakistanPhilippinesQatarSingaporeSouth KoreaSouth of PalestineThe Kingdom of Saudi ArabiaUnited Arab EmiratesYemen
Evidence
Proven to prevent and treat wound infection
Proven in more than 40 clinical studies and in publications including over 7,000 patients, Sorbact® has more than 30 years of successful use in clinical practice. Today Sorbact® is helping patients in over 65 countries around the world and we are continuing this important work by collecting clinical data.
This is a selection of scientific articles about Sorbact®.
Studies
-
Evidence is building to support using a DACC-coated antimicrobial wound contact layer with NPWTWounds UK. 11(1):82-86
-
Efficacy of Dialkylcarbamoylchloride-Coated Dressing in Management of Colonized or Infected Neonatal and Pediatric WoundsJ Wound Ostomy Continence Nurs. 43(4):547-550
-
Dialkylcarbamoyl Chloride Dressings in the Prevention of Surgical Site Infections after Nonimplant Vascular SurgeryAnn Vasc Surg. 44:387-392
-
The use of DACC-coated dressings for the treatment of infected, complex abdominal woundsWounds UK. 8(4):102-109
-
Bacterial-binding dressings in the management of wound healing and infection prevention: A narrative reviewJ Wound Care. 28(6):370-382
-
Hydrogel-impregnated dressings for graft fixation: A case seriesJ Wound Care. 24(7):326-328
-
The effect of a bacteria- and fungi-binding mesh dressing on the bacterial load of pressure ulcers treated with negative pressure wound therapy: A pilot studyWounds. 28(11):408-420
-
Binding of two bacterial biofilms to dialkyl carbamoyl chloride (DACC)-coated dressings in vitroJ Wound Care. 25(2):76, 78-82
-
Clinical efficacy of dialkylcarbamoylchloride-coated cotton acetate dressing versus combination of normal saline dressing and 2 % mupirocin ointment in infected wounds of epidermolysis bullosaDermatologic therapy. 32(5):e13047
-
Panbacterial real-time PCR to evaluate bacterial burden in chronic wounds treated with Cutimed SorbactEur J Clin Microbiol Infect Dis. 31(7):1523-1529
-
Adhesion of the ulcerative pathogen Mycobacterium ulcerans to DACC-coated dressingsJ Wound Care. 23(8):417-418, 422-424
-
An evaluation of the efficacy of Cutimed Sorbact in different types of non-healing woundsWounds UK. 3(4):113-119
-
Use of DACC-coated dressings in diabetic foot ulcers: A case seriesDiabet Foot J. 14(3):133-137
-
Open study on the topical treatment of interdigital fungal infections in diabetic patientsJ Wound Care. 18(11):470, 472-473
-
An investigation of Cutimed Sorbact as an antimicrobial alternative in wound managementWounds UK. 4(2):10-18
-
Using the principle of hydrophobic interaction to bind and remove wound bacteriaJ Wound Care. 15(4):175-180
-
Comparison of bacteria and fungus‐binding mesh, foam and gauze as fillers in negative pressure wound therapy – pressure transduction, wound edge contraction, microvascular blood flow and fluid retentionInt Wound J. 10(5):597-605
-
Use of bacteria- and fungus-binding mesh in negative pressure wound therapy provides significant granulation tissue without tissue ingrowthEplasty. 14:e3
-
Comparative study of two antimicrobial dressings in infected leg ulcers: a pilot studyJ Wound Care. 24(3):121-122, 124-127
-
Clinical evaluation of Sorbact in the treatment of infected pressure soresActa Vulnologica. 2(1-2):9-11
-
Evaluating Cutimed Sorbact: Using a Case Study ApproachBr J Nurs. 18(15):30, 32-36
-
Dialkylcarbamoyl chloride-coated versus alginate dressings after pilonidal sinus excision: a randomized clinical trial (SORKYSA study)BJS Open. 4(2):225-231
-
Adhesion of meticillin-resistant Staphylococcus aureus to DACC-coated dressingsJ Wound Care. 23(10):484, 486-488
-
The diabetic foot: managing infection using Cutimed Sorbact dressingsBr J Nurs. 19(11):30, 32-36
-
Randomized controlled trial evaluating dialkylcarbamoyl chloride impregnated dressings for the prevention of surgical site infections in adult women undergoing cesarean sectionSurg Infect (Larchmt). 17(4):427-435
-
Cost-effectiveness of a bacterial-binding dressing to prevent surgical site infection following caesarean sectionJ Wound Care. 28(4):222-228
-
Dialkylcarbamoyl chloride-impregnated dressing for the prevention of surgical site infection in women undergoing cesarean section: a pilot studyArch Med Sci. 12(5):1036-1042
-
Cutimed® Siltec foam and Cutimed® Sorbact® gel dressings: a clinical auditWounds UK. 6(1):130-136
-
Dialkylcarbamoyl chloride (DACC)-coated dressings in the management and prevention of wound infection: A systematic reviewJ Wound Care. 26(3):107-114
-
A pilot feasibility randomised clinical trial comparing dialkylcarbamoylchloride-coated dressings versus standard care for the primary prevention of surgical site infectionInt Wound J. 16(4):1-8
Posters
-
DACC coated wound dressing and endotoxin: Investigation on binding ability and effect on endotoxin release from gram-negative bacteriaEWMA 2019. EP167
-
Significant and rapid reduction of free endotoxin concentration by dialkylcarbamoyl chloride (dacc)-coated wound dressingSAWC 2020. LR-077
-
Evaluation of moisture donating capacity of six different wound gels in vitroEWMA 2019. PP019
-
Antimicrobial effect of a DACC-coated bacteria-binding wound dressing against WHO pathogensEWMA 2020. EP006
Consensus and Guidelines
-
EWMA Document: Negative pressure wound therapy overview, challenges and perspectivesJ Wound Care. 26(3):1-113
-
Implementing Timers: the race against hard-to-heal woundsJ Wound Care. 28(3):1-49
-
Risk, prevention and management of complications after vaginal and caesarean section birthJ Wound Care. 29(Sup11a)
-
Leukomed Sorbact for preventing surgical site infectionNICE National Institute for Health and Care Excellence. 1-11
-
Identifying and treating foot ulcers in patients with diabetes: saving feet, legs and livesJ Wound Care. 27(Sup5):1-52
-
Surgical site infection: preventing and managing surgical site infection across health care sectorsJ Wound Care. 29(Sup2b):1-72